This and the fact that CD137L-DCs have been shown to stimulate proliferation, IFN-γ secretion and the cytolytic activity of T cells more potently than GM-CSF and IL-4 derived DCs14, 15, 16, advocate the evaluation of CD137L-DCs as vaccines in human tumour immunotherapy. This evidence concerns the gene IFNG and neoplasm.